Markets
US-AI-TECH-COMPUTERS-TELECOM
Jensen Huang (Patrick T. Fallon/Getty Images)

Wall Street’s key takeaways from Nvidia CEO Jensen Huang’s speech and analyst Q&A at CES

Jensen Huang talks, Wall Street reacts.

Luke Kawa

When the leader of the biggest publicly traded company in the world delivers a 90-minute presentation, Wall Street is going to have some things to say about it.

Here’s what the sell side highlighted from Nvidia CEO Jensen Huang’s keynote address at the Consumer Electronics Show in Las Vegas on Monday, as well as the Q&A that the company held with analysts.

JPMorgan analyst Harlan Sur:

  • The confirmation that Vera Rubin chips are in full production and poised for a ramp in the second half of this year should be seen as “putting to rest recent concerns about potential delays.”

  • “NVDA has deftly positioned itself to benefit from multiple aspects of physical AI development — from data center compute (model training), to simulation (Omniverse) to edge devices (Jetson Thor) — which in aggregate could potentially drive the next leg of revenue growth for NVDA,” with Jensen Huang indicating that the AV revenue opportunity would be well above $10 billion by 2030.

  • The steady drumbeat of Nvidia championing the benefits of its GPUs relative to custom chips continues. The chip designer is “arguing that rivals (i.e. AI XPUs) will be hard pressed to keep pace with the performance of Vera Rubin and subsequent platforms with a ‘one chip at a time’ approach to design. We think to some degree there is validity to this notion, though growth in XPU volumes also clearly point to a TCO [total cost of ownership] benefit that hyperscalers are able to realize (in other words, AI ASICs continue to gain traction and capture share despite NVDA’s dominance in pure performance).”

  • It’s leaning in to inference-specific offerings: “NVDA also introduced a new context memory storage controller that aims to address the challenge of increasingly large context windows, opening up a new TAM [total addressable market] for the company where we think it will quickly gain traction with customers given the seamless integration of this storage system into its Vera Rubin platform offering.”

Morgan Stanley analyst Joseph Moore:

  • “Management described Rubin as being in ‘full production,’ highlighting meaningful improvements to manufacturability at the system level following their learnings with Blackwell. Rubin compute board assembly time has been reduced to ~5 minutes versus ~2 hours for Blackwell, and we saw on video the first rack being deployed. The timeline for launch remains second half of 2026, but revenue should be material around that time.”

  • “Management highlighted its unique position as the only chip company procuring these large quantities of DRAM and HBM directly, and with so much of the ecosystem supporting their growth they see themselves as having an advantage due to that scale.”

  • “No major surprises, but confidence on Rubin should be positively received given competitive noise exiting 2025 around broader TPU traction. While the obvious pushback is that Rubin specs and timelines haven’t changed, the stock is still 10% below highs immediately following Jensen’s $500 billion comments at GTC DC, numbers which have since moved higher post earnings and were reinforced in spirit today during the Q&A and fireside. With no hedging on supply or demand, we think enthusiasm can return as that plays out in numbers this year.”

Bank of America analyst Vivek Arya:

  • “AI scaling remains on track, with 5x token generation, 10x token cost reduction per year.”

  • Answering the where-does-the-money-come-from question: “AI to be funded by modernization of AI (repurposing $10 trillion of computing funding last decade), shifting of R&D methods.”

  • China H200 demand is there, but still awaiting licenses”

Wedbush Securities analyst Dan Ives:

  • Overall, Huang’s address “fully set the tone for the AI Revolution heading into 2026 as the company laid the path for the next stage of the AI Revolution: physical AI.”

  • On Nvidia’s Alpamayo platform for autonomous vehicles: “We believe this new foundation model designed for AVs are an incremental positive for Tesla as the company looks to accelerate its autonomous vehicle technology and capitalize on the AV industry over the next decade.”

  • “We walked out of the event feeling even more bullish about Nvidia and the overall AI Revolution as the next stage of investments and technology are on the horizon that can facilitate a new age for the technology world with companies around the world are set to capitalize on $3 trillion to $4 trillion of AI Cap Ex hitting the market over the next 3 years.”

More Markets

See all Markets
President Trump Delivers An Announcement From The Oval Office

Pharma largely unfazed as Greenland tariffs roil markets

Drugmakers, which have spent the past six months reaching tariff deals with Trump, seem to expect some immunity from a new batch of tariffs on European countries.

markets

POET Technologies nears multiyear high on strong call demand after flagship product wins award

POET Technologies is surging on heavy volumes and high call demand after announcing that it won a Product Innovation Award at China’s Infostone awards.

The honor went to the optical communications company’s flagship product, the Teralight, which uses light to move data between chips.

“Unveiled less than a year ago at the 2025 OFC Conference, POET Teralight has driven commercial interest in the Company because of its highly integrated design and complete optical system-on-chip architecture that simplifies module development,” per the press release.

This award may be the latest excuse to buy the stock, which is up over 40% year to date.

Call activity is elevated, with nearly 37,000 having changed hands as of 10:55 a.m. ET, well above the 20-day average of 28,030 for a full session. Shares are approaching their multi-year high of $9.41.

markets

Intel bucks market slump after Wall Street upgrades

While the market slid early Tuesday, Intel soared as the American chipmaker received a pair of upgrades:

  • HSBC analysts lifted their rating on the stock to “hold” — essentially “neutral” — from “reduce,” Wall Street-speak for “sell.” The analysts nearly doubled their price target for the shares to $50 from $26. (That’s essentially where the stock is currently trading.)

  • Seaport Global also boosted its rating to “buy” from “neutral,” with a $65 price target.

Improving demand for CPUs — Intel’s bread-and-butter processors — is behind HSBC’s newfound enthusiasm for the shares. Analysts at the bank wrote:

“We had been cautious on Intel mainly given overall uncertainty on customer pipeline and execution headwinds in their foundry business while the core business was also lacking visibility on growth drivers. However, we now turn more positive as we expect the traditional servers (DCAI) to get back on a growth trajectory. We expect there is an overwhelmingly increasing demand for server CPUs driven by rising agentic AI... While the stock has moved up 19% YTD (vs S&P 500 up 1%), we believe there is further [data center and AI group] upside still not fully priced in. Hence, we upgrade Intel from Reduce to Hold.”

HSBC seems to be slightly understating the extent of the gains for the stock so far in 2026, as its share price has risen nearly 30% since the end of last year. But the gains are even more impressive if you date them to the partial nationalization of the ailing American chip giant, which was announced on August 22. Almost a month later, Nvidia announced a strategic partnership with the company, giving it a massive shot in the arm. Since then the stock is up more than 90%.

markets

ImmunityBio surge continues on sign its drug may be approved to treat a broader range of bladder cancers

Once you start squeezing, you can’t put the toothpaste back in the tube.

Shares of ImmnuityBio are flying higher once again, up more than 30% in early trading Tuesday after having been down as much as 10% in the premarket. A little more than half an hour into the regular trading day, more than 46 million shares have changed hands, more than 3x the 20-day average for this point in the session.

Last week, we discussed how a number of positive press releases from the company touting the progress of its treatments helped send shares skyward, making the heavily shorted company a hot topic of discussion on the r/ShortSqueeze subreddit.

The positive press parade continues this morning, with ImmunityBio announcing that the FDA asked for more information about the ability of its ANKTIVA drug to treat a certain type of bladder cancer, though it doesn’t need to do any new clinical trials. Management said they would provide this information within 30 days.

Share are up nearly 200% over the past six sessions.

On Monday, the company published a podcast appearance by Dr. Patrick Soon-Shiong, founder, executive chairman, and global chief medical and technology officer, on “The Sean Spicer Show,” which was provocatively titled, “Is the FDA BLOCKING Life Saving Cancer Treatments?”

markets

AppLovin craters after report from CapitalWatch alleges it’s a money-laundering operation for “transnational criminal kingpins”

AppLovin is tumbling in premarket trading on Tuesday after financial research agency CapitalWatch published a report on Monday calling the company “the ultimate monument to 21st-century new-type transnational financial crime.”

“AppLovin serves as the ultimate exit for asset laundering/diversion by transnational criminal kingpins,” the authors wrote, alleging that the growth of its advertising business comes in part from illicit cryptocurrency funds routed through its platform.

AppLovin did not immediately respond to a request for comment from Sherwood News.

This is far from the first report to question AppLovin’s business practices.

Fuzzy Panda Research and Culper Research announced short positions in the ad tech firm last February in research reports alleging that AppLovin’s operating performance was a function of “systematic exploitation of app permissions” as well as taking data and gaming the ad platforms of other tech giants, particularly Meta. In October, reports surfaced that the SEC was investigating AppLovin’s data collection practices, as were a number of state regulators.

The allegations raised by CapitalWatch are a whole different kettle of illegal fish.

Anything is possible. But if I were hypothetically trying to launder a bunch of money, I likely would not try to do so through a publicly traded entity domiciled in the United States that’s subject to much more regulatory oversight and scrutiny than the average global firm.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.